A compound of Formula I, or a pharmaceutically acceptable salt, hydrate and/or prodrug thereof, wherein: E and G are each independently selected from the group consisting of C 1-4 alkyl, -NH-, -N(C 1-4 alkyl)-, -O- and, in either orientation, -NH-C 1-4 alkyl-, -N(C 1-4 alkyl)-C 1-4 alkyl-, and -O-C 1-4 alkyl-; and ---- is a single bond; K is independently selected from CH and N, and J is independently selected from NH and CH 2; R 1 and R 2 are each 0-2 substituents wherein each substituent is independently selected from the group consisting of -C 1-4 alkyl, -OH, -O-C 1-4 alkyl, -N(R 4) 2, -C 1-4 alkylN(R 4) 2, -NO 2 halogen, and CF 3; each R 4 is independently selected from the group consisting of H, OH, -C 1-4 alkyl, -C OC 1-4 alkyl, and -C R 8, provided that if one R 4 is OH then the other R 4 cannot be OH; or -N(R 4) 2 forms a pyrrolidinyl, piperidinyl, piperazinyl, or morpholino group optionally substituted with methyl; R 5 is selected from the group consisting of -C 1-4 alkyl and phenyl; R 3 is selected from the group consisting of H, -C 1-4 alkyl, aryl, and alkylaryl; and wherein said prodrug is selected from (i) a compound in which an amino acid residue, or a polypeptide chain of two or more amino acid residues are covalently joined to a free amino, hydroxyl or carboxylic acid group of the compound of formula I, (ii) a compound in which a carbonate, carbamate, amide or alkyl ester is covalently bonded to a free amino, hydroxyl, or carboxylic acid group of the compound of formula I through the carbonyl carbon prodrug sidechain, or (iii) a compound comprising a phosphate derivative of a compound of formula I joined through a phosphorous-oxygen bond to a free hydroxyl of compounds of formula I; wherein the phosphate derivative is a phosphate acid, a salt of a phosphate acid or a phosphate ester. E and G are each independently selected from the group consisting of C 1-4 alkyl, -NH-, -N(C 1-4 alkyl)-, -O- and, in either orientation, -NH-C 1-4 alkyl-, -N(C 1-4 alkyl)-C 1-4 alkyl-, and -O-C 1-4 alkyl-; and ---- is a single bond; K is independently selected from CH and N, and J is independently selected from NH and CH 2; K is independently selected from CH and N, and J is independently selected from NH and CH 2; R 1 and R 2 are each 0-2 substituents wherein each substituent is independently selected from the group consisting of -C 1-4 alkyl, -OH, -O-C 1-4 alkyl, -N(R 4) 2, -C 1-4 alkylN(R 4) 2, -NO 2 halogen, and CF 3; each R 4 is independently selected from the group consisting of H, OH, -C 1-4 alkyl, -C OC 1-4 alkyl, and -C R 8, provided that if one R 4 is OH then the other R 4 cannot be OH; or -N(R 4) 2 forms a pyrrolidinyl, piperidinyl, piperazinyl, or morpholino group optionally substituted with methyl; R 5 is selected from the group consisting of -C 1-4 alkyl and phenyl; each R 4 is independently selected from the group consisting of H, OH, -C 1-4 alkyl, -C OC 1-4 alkyl, and -C R 8, provided that if one R 4 is OH then the other R 4 cannot be OH; or -N(R 4) 2 forms a pyrrolidinyl, piperidinyl, piperazinyl, or morpholino group optionally substituted with methyl; R 5 is selected from the group consisting of -C 1-4 alkyl and phenyl; R 3 is selected from the group consisting of H, -C 1-4 alkyl, aryl, and alkylaryl; and wherein said prodrug is selected from (i) a compound in which an amino acid residue, or a polypeptide chain of two or more amino acid residues are covalently joined to a free amino, hydroxyl or carboxylic acid group of the compound of formula I, (ii) a compound in which a carbonate, carbamate, amide or alkyl ester is covalently bonded to a free amino, hydroxyl, or carboxylic acid group of the compound of formula I through the carbonyl carbon prodrug sidechain, or (iii) a compound comprising a phosphate derivative of a compound of formula I joined through a phosphorous-oxygen bond to a free hydroxyl of compounds of formula I; wherein the phosphate derivative is a phosphate acid, a salt of a phosphate acid or a phosphate ester.